The company has developed over 20 algorithms for a range of conditions including cancer, Alzheimer’s, osteoarthritis and liver disease.
It has recently launched chest X-ray and CT scan products for COVID-19, to support early detection through imaging biomarkers. Its products are used in over 70 hospitals and 11 clinical trials across the world, and has processed 6.5 million images to date.
With the investment the company plans to expand its range of algorithms and components available through its AI-based radiology platform.
Angel Alberich Bayarri, founder and CEO of QUIBIM, said: “QUIBIM is now at a scale-up point ready to grow internationally while maintaining great science at the core of our mission.”
“This latest round of funding will be used to boost the AI platform, our available algorithms and high-value components, to provide a seamless, all-in-one solution supporting healthcare providers.”
“Our new investors will open opportunities for us in new markets and help us to strengthen our brand internationally. We will be able to promote our new prostate, musculoskeletal and oncology solutions and increase sales globally, by expanding our workforce over the coming year.”
Rocio Pillado, partner at Adara Ventures, said: “We are excited by the potential of radiomics to improve disease detection and enable precision treatments guided by imaging biomarkers.”
Related
- Digital Health and Care Wales to move to cloud pathology…
- MyOpNotes awarded Innovate UK funding to support integration…
- Log my Care announces additional £3m in funding to expand…
- Black Country Local Maternity and Neonatal System implements…
- NHS Education for Scotland shares plans to update digital…
- Interview: Wendy Blumenow on the benefits of the Isla remote…
